OC 34

ONCO-FETAL REPROGRAMMING DRIVES HIGH-RISK JUVENILE MYELOMONOCYTIC LEUKEMIA, WHICH CAN BE TARGETED BY ANTI-CD52 TREATMENT

Mark Hartmann [1], Maximilian Schönung [1], Jovana Rajak [2], Joschka Hey [3], Valentin Maurer [1], Ling Hai [4], Sina Staeble [1], Jens Langstein [1], Katharina Bauer [5], Mariam Hakobyan [1], Laura Jardine [6], Sheila Bohler [2], Dominik Vonficht [7,13], Abdul-Habib Maag [8], Dirk Lebrecht [2], Katrin M. Bernt [9], Roland Roelz [10], Tobias Boch [11], Eleonora Khabirova [12], Pavlo Lutsik [3], Simon Haas [14], Muzlifah Haniffa [6], Sam Behjati [12], Jan-Philipp Mallm [5], Christian Buske [8], Michael D. Milsom [7,15], Stefan Fröhling [16,17], Marc-Jan Bonder [18,19,20], Charlotte Niemeyer [2], Christian Flotho [2,17], Christoph Plass [3], Miriam Erlacher [2,17], Matthias Schlesner [21], Daniel B. Lipka [1]

[1] Section of Translational Cancer Epigenomics, Division of Translational Medical Oncology, German Cancer Research Center (DKFZ) & National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg, Germany
[2] Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany
[3] Division of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany
[4] Department of Neurology and Neurooncology, University Hospital Heidelberg, Heidelberg, Germany
[5] scOPEN Lab, German Cancer Research Center (DKFZ), Heidelberg, Germany
[6] Biosciences Institute, Newcastle University, Newcastle upon Tyne NE2 4HH, UK
[7] Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany
[8] Institute of Experimental Cancer Research, University Hospital of Ulm, Ulm, Germany
[9] Division of Pediatric Oncology, Children's Hospital of Philadelphia, Philadelphia, USA
[10] Department of Neurosurgery, University of Freiburg, Faculty of Medicine, Medical Center, Freiburg, Germany
[11] Department of Hematology and Oncology, Heidelberg University, University Hospital Mannheim, Mannheim, Germany
[12] Wellcome Sanger Institute, Hinxton, UK
[13] Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany
[14] Berlin Institute of Health (BIH), Charité - Universitätsmedizin Berlin, Berlin, Germany
[15] Division of Experimental Hematology, German Cancer Research Center (DKFZ), Heidelberg, Germany
[16] Division of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg & German Cancer Research Center (DKFZ), Heidelberg, Germany
[17] German Cancer Consortium (DKTK), Heidelberg, Germany
[18] Division of Computational Genomics and Systems Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany
[19] Genome Biology Unit, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany
[20] European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, European Molecular Biology Laboratory (EMBL), Hinxton, United Kingdom
[21] Faculty of Applied Computer Sciences, Biomedical Informatics, Data Mining and Data Analytics, University of Augsburg, Augsburg, Germany

Background and aims: Juvenile myelomonocytic leukemia (JMML) is caused by genetic activation of RAS signaling and has a heterogeneous clinical course. JMML epitypes resolve this heterogeneity but high-risk patients lack efficient curative treatment options. To date, the mechanisms driving disease heterogeneity remain unclear. This study aimed to decipher the underlying molecular programs in order to identify disease-specific aberrations for diagnostic and therapeutic purposes.

Methods: We employed a multi-omics approach to dissect the epitype-specific molecular programs in primary JMML patient samples. Our findings were validated using an inducible *Ptpn11-E76K* knock-in mouse and a patient-derived xenotransplantation (PDX) model.

Results: Multi-modal analysis demonstrated conservation of epigenetic subgroups in hematopoietic stem cells (HSCs) of JMML patients. Epigenomic dysregulation affected binding motifs of developmental transcription factors and correlated with ectopic expression of fetal HSC signatures in high-risk patients, including *HMGA2* and fetal hemoglobin. Mapping JMML HSC methylomes onto the normaldevelopmental trajectory from fetal to adult HSCs, generally revealed a post-natal HSC state. However, high-risk JMML HSCs were epigenetically more immature and presented fetal-like methylation patterns. Employing a JMML mouse model with postnatal induction of the *Ptpn11-E76K* mutation resulted in reactivation of fetal-like expression programs in HSCs akin to those observed in high-risk JMML, suggesting that high-risk JMML HSCs hijack fetal programs. In line with this, integrative analysis identified several subgroup-specific molecular markers which might serve as prognostic biomarkers for high-risk JMML. One of those markers, CD52, was both differentially methylated and highly expressed in high-risk JMML HSCs. Targeting CD52 with alemtuzumab in a JMML PDX mouse model demonstrated reduced human engraftment in treated recipients and increased survival of 2° recipients.

Conclusions: In summary, we identified onco-fetal reprogramming as a hallmark of high-risk JMML. We determined unique molecular programs which can be used to develop new treatment strategies for high-risk JMML and provide pre-clinical evidence for anti-leukemic activity of alemtuzumab.

Keywords: JMML, Multi-OMICS, targeted treatment, biomarkers